AccuStem Sciences Inc - SIC # 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ACUT Over the counter 2835 https://accustem.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AccuStem Sciences Inc

AccuStem Sciences, Inc. and EmeritusDX Announce Joint Product Development Agreement and Strategic Partnership - Jul 17th, 2023 11:00 am
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer - Jul 11th, 2023 11:00 am
Goldman Small Cap Research Publishes New Research Report on AccuStem Sciences, Inc. - Jun 20th, 2023 12:09 pm
AccuStem Sciences, Inc. Announces Collaboration Agreement with University Hospitals - Jun 6th, 2023 5:00 am
AccuStem Announce Strategic Clinical and Operational Partnership - May 31st, 2023 11:00 am
AccuStem Sciences Announces Extension of its US Patent Application for SPARE Test for Patients with Breast Cancer - May 2nd, 2023 11:00 am